In the article by Uojima et al. entitled “Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib” [Liver Cancer. 2020; 9:193–206, DOI: 10.1159/000504604], the authors found that “SMI = subcutaneous fat area (cm2) / height2 (m2)” was used erroneously instead of “SMI = skeletal mass area (cm2) / height2 (m2)” in the labelling of Figure 2. Figure 2 with the correct labelling is shown here.
. 2022 Oct 4;11(6):581. doi: 10.1159/000525946
Erratum
Collection date 2022 Dec.
Copyright © 2022 by The Author(s) Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
PMCID: PMC9801174 PMID: 36589731
This corrects the article "Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib" in volume 9 on page 193.